We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Status: Active

Dec 1st 2020 - Dec 31st 2020

Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.

read more read less

Her.9 Rating Review

Pitch rating powered by CROWDRATING

Rated on 08/12/2020

Pitch Rated

50%

Insufficient Data

Management

83%

Product

66%

Investment

UNRATED*

* Section unrated owing to insufficient or incomplete information available at the time of rating.

Log in to view amount pledged

    Log in to view target

    £2,500,317
    pre-money valuation

    5.66%
    equity available

    256
    investors

    £844
    pledge per investor

    12559715
    company number

    Active
    company status

    16/04/2020
    incorporated 4 years

    £1.66
    share price

    Previous Funding rounds
    23 Apr 24 Crowdcube £215,946 / 144% 49.67%

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 83%

Skills 91%
The management team at Her.9 includes skilled professionals with expertise in their functional areas, streamlining its overall operations. It consists of three experienced founders, a Head of Product, and a Head of Logistics. The Founder/CEO is a senior executive with expertise in business strategy, manufacturing, and new venture development. He is a CEO/CFO certified and has prior experience of working at the same stage of business growth. He also takes responsibility as the finance head in the company and advises the company on various financial aspects. The other two co-founders supervise the marketing department, both of them being seasoned executives with a track record in the marketing field of successfully operating in several start-ups. They have expertise in start-ups, social media, and marketing. The Head of Product is a leading private Bristol nutritionist and functional medicine practitioner. She specialises in nutritional counselling, wellness coaching, supplements, and pediatric nutrition. The Head of Logistics is competent in change management, service-oriented architecture, supply chain management, and operations management.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001

Log in to view amount pledged

    Log in to view target

    £2,500,317
    pre-money valuation

    5.66%
    equity available

    256
    investors

    £844
    pledge per investor

    12559715
    company number

    Active
    company status

    16/04/2020
    incorporated 4 years

    £1.66
    share price

    Previous Funding rounds
    23 Apr 24 Crowdcube £215,946 / 144% 49.67%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph